Performance and Economic Comparison of Solar Cooling Configurations

In this paper a performance and economic comparison of solar cooling configurations using a new integrated approach combining the hourly thermal-optical performance assessment of the solar systems with the economic aspects has been conducted. Evacuated tube solar collectors with single effect LiBr absorption chiller and compact solar linear concentrating Fresnel collectors with single effect or medium temperature double effect LiBr absorption chiller have been taken into account. Considering that all the produced cold thermal energy could be delivered to a final user, the latter solar cooling configuration shows the possibility to have the Levelized Cost Of Cooling (LCOC) comparable with standard electric compression cooling. However, technology improvements and economy of scale are necessary in order to reduce solar field cost in the range 150-250 €/m2

Levelized Cost of Heat for Linear Fresnel Concentrated Solar Systems

In this paper, a deep investigation upon levelized cost of heat (LCOH) produced by small-scale solar linear concentrating Fresnel collectors (CSLFC) is proposed. Solar industrial process heat applications have temperature requirements from about 60 °C to 260 °C. CSLFCs can effectively integrate conventional fossil fuel thermal systems. The study is addressed to assess technology cost projection needed to achieve competitive LCOH. So, on the basis of a framework specifically developed for these economic assessments, the best investment scenarios, in terms of industrial application, geographical location and technical design solutions, where to effectively apply the technology of CSLFC, are highlighted. The analysis has been focused on specific cost of several existing CSLFCs associated with declared performances at different operating temperatures. Two main classes of CSLFC with different total efficiency (optical and thermal) corresponding to various design solutions and specific cost were selected. The expected performances in the whole application temperature range have been evaluated through Glayx Tech proprietary simulation code, including optical and thermal unsteady analysis. A huge database coming from full CSLFC simulation varying latitude, yearly DNI, operating fluid, outlet temperature, thermal storage options, has been collected. CLSFC design and performance requirements are the key-choice to achieve competitive LCOH: the use of high efficiency – high cost components is not always rewarding in terms of final LCOH and must be attentively decided basing on site, irradiation, heat quality and LCOH target. In this perspective, CLSFCs are the most promising for industrial small scale heat applications since they show the greatest potential to reduce manufacturing costs

In vitro-generated interspecific recombinants between bovine herpesviruses 1 and 5 show attenuated replication characteristics and establish latency in the natural host

peer reviewe

Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study

Background: The role of chemotherapy in the treatment of metastatic male breast cancer patients remains unknown, and the only available evidence stem from small, retrospective series evaluating outdated drugs and/or regimens. Methods: In this retrospective study we evaluated the activity of polychemotherapy, consisting of three-drug (anthracycline-containing and anthracycline-free) regimens, as a first-line therapy for metastatic male breast cancer patients who had received at least one prior endocrine therapy. Results: Fifty patients treated between 1978 and 2013 were included in the present analysis. Regarding best response, we recorded 1 (2%) complete response and 27 (54%) partial responses, for an overall response rate of 56% (95% CI, 42.2-69.8). Considering stable disease, the disease control rate was 84%. Median progression-free survival was 7.2 months (95% CI, 5.9-8.5), and median overall survival was 14.2 months (95% CI, 12.2-16.2). Albeit we observed some differences for all the outcomes explored when comparing anthracycline-containing and anthracycline-free regimens, they were not statistically significant. Conclusions: Chemotherapy, consisting in both anthracycline-containing and anthracycline-free regimens, showed encouraging antitumor activity in metastatic male breast cancer patients previously treated with endocrine therapy

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

We analyzed data from 738 HER2\u2010positive metastatic breast cancer (mbc) patients treated with pertuzumab\u2010based regimens and/or T\u2010DM1 at 45 Italian centers. Outcomes were explored in relation to tumor subtype assessed by immunohistochemistry (IHC). The median progression free survival at first\u2010line (mPFS1) was 12 months. Pertuzumab as first\u2010line conferred longer mPFS1 compared to other first\u2010line treatments (16 vs 9 months, p=0.0001), regardless of IHC subtype. Median PFS in second\u2010line (mPFS2) was 7 months, with no difference by IHC subtype, but it was more favorable with T\u2010DM1 compared to other agents (7 vs 6 months, p=0.03). There was no PFS2 gain in patients with tumors expressing both hormonal receptors (HRs) (p=0.17), while a trend emerged for tumors with one HR (p=0.05). Conversely, PFS2 gain was significant in HRs\u2010negative tumors (p=0.04). Median overall survival (mOS) was 74 months, with no significant differences by IHC subtypes. Survival rates at 2 and 3 years in patients treated with T\u2010DM1 in second\u2010line following pertuzumab were significantly lower compared to pertuzumab\u2010na\uefve patients(p=0.01). When analyzed by IHC subtype, the outcome was confirmed if both HRs or no HRs were expressed (p=0.02 and p=0.006, respectively). Our results confirm that HRs expression impacts the clinical behavior and novel treatment\u2010related outcomes of HER2\u2010positive tumors when treatment sequences are considered. Moreover, multivariate analysis showed that HRs expression had no effect on PFS and OS. Further studies are warranted to confirm our findings and clarify the interplay between HER2 and estrogen receptor (ER) pathways in HER2\u2010positive (mbc) patients

Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic

This study aimed to describe the change in surgical practice and the impact of SARS-CoV-2 on mortality after surgical resection of colorectal cancer during the initial phases of the SARS-CoV-2 pandemic